IBA proudly releases myQA®: New Global Quality Assurance Platform The All-in-One, All Connected, and All Secure solution.

Posted on Mar 24, 2015

Schwarzenbruck, Germany, March 25, 2015 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, announces the release of the new global quality assurance platform: myQA®. myQA offers full support throughout all QA applications and provides the user access to their various software modules and data from oneintuitive platform – anytime and anywhere.

"myQA has given me the ability to have full control of my data by connecting all QA applications onto one platform and into one central database. This platform allows me to cross-check data from within the various softwares, and offers the unique opportunity to connect with peers from around the world and benchmark QA data using the myQA Cloud,” says Dr. Luis Brualla González, Hospital General Universitario, ERESA, Valencia, Spain."With myQA, the quality assurance becomes schedulable - in every sense of the word. For example, right now I am programming QA activities after Linac interventions using subgroups from periodic QA tasks, according to technical service recommendations. Another highlight for me is the myQA Cockpit. This web-based dashboard will allow us to quickly retrieve machine QA status updates anywhere in the department. myQA is truly an all-in-one solution."

The myQA Platform offers an all-in-one interface that completely redesigns how the user is able to manage and organize their QA applications. It enhances the QA workflow and maximizes efficiency by integrating all QA software modules into one platform and one Central Database (SQL) – which is accessible throughout the department and even satellites. Using the myQA Cockpit, users can maintain connectivity by reviewing and tracking their patient data and machine QA status from anywhere and on various devices, including smartphones and tablets. It also allows the user to keep an instant overview with simple and clear reporting on one screen. With the myQA Cloud, the user is given a unique outlet to perform bench-marking of their QA data for best practice checks and full trust in their results. The myQA Cloud grants users the opportunity to anonymously connect with peers and data from around the world.


“We are delighted to announce the release of the new global quality assurance platform, myQA. This highly anticipated solution has already generated a large amount of positive feedback and excitement from the market,” says Andreas Strempfl, Product Manager of myQA at IBA Dosimetry. “myQA is designed to assist our customers in effectively and efficiently maintaining a productive QA workflow. The various modules available within the myQA Platform are optimized to save the user a great deal of time through connectivity, data crosschecking, and the ability to retrieve instant status updates using browser-based web clients, such as tablets and smartphones. I am very excited to continue to grow with our users as we embark on this myQA journey together.”

"The release of the myQA software platform is a milestone for IBA Dosimetry. It will enable our customers to measure and handle big data in an efficient and reliable way. Furthermore, the release of myQA is a big step towards our vision in connecting our global users with each other," continues Rob Plompen, President of IBA Dosimetry. "I therefore would like to thank all of the staff involved as well as our business- and clinical partners for their outstanding efforts and insights in releasing myQA as a true clinical workflow-based software platform.”

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.ibaworldwide.com


This page was printed from OSL Web site at http://www.osl.uk.com